LAURUSLABS - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:03 am

IntraDay Trade Rating: 4.1

📊 Analysis: LAURUSLABS is trading at ₹1,047, very close to its 52-week high (₹1,049), reflecting strong bullish sentiment. RSI at 57.0 indicates healthy momentum, while MACD (10.2) confirms positive undertone. Current price is well above both 50 DMA (₹974) and 200 DMA (₹818), showing sustained uptrend. Intraday volume (8,89,160) is slightly below the 1-week average (10,26,774), suggesting moderate participation. Fundamentals show strong quarterly PAT growth (+408%), though valuation is stretched with a P/E of 82.8 vs industry 30.6 and relatively weak ROE (7.75%).

💡 Optimal Buy Price: ₹1,040–1,045 if price consolidates near support.

🎯 Profit-Taking Exit Levels: ₹1,055 (minor resistance), ₹1,070 (short-term breakout zone).

🛡️ Stop-Loss: ₹1,030 to protect against downside risk.

⏱️ If Already Holding: Exit intraday if price fails to hold above ₹1,040 or RSI dips below 55 with declining volume. A breakout above ₹1,055–1,070 can be used for profit booking.

Positive

• 📈 PAT growth from ₹158 Cr. to ₹216 Cr. (+408%)
• 💰 EPS at ₹12.6 reflects earnings improvement
• 🏭 Price trading well above both 50 DMA and 200 DMA
• 🔄 FII holdings increased (+0.47%)

Limitation

• ⚠️ High P/E (82.8) compared to industry average (30.6)
• 📉 ROE (7.75%) and ROCE (9.47%) relatively weak
• 📊 Intraday volume slightly below weekly average
• ⚠️ PEG ratio (-3.57) signals poor valuation-growth alignment

Company Negative News

• 📉 Valuation stretched vs peers
• ⚠️ Weak return ratios despite strong PAT growth
• 🔻 Decline in DII holdings (-0.22%)

Company Positive News

• 📈 Strong quarterly PAT growth (+408%)
• 💡 EPS improvement supports profitability outlook
• 💰 Dividend yield of 0.12% adds shareholder value

Industry

• 🏥 Pharma sector supported by global demand for APIs and formulations
• 📊 Industry PE at 30.6, much lower than company valuation
• 🌍 Long-term demand outlook remains positive with healthcare expansion

Conclusion

⚖️ LAURUSLABS shows strong momentum and PAT growth, trading near its 52-week high. Suitable for intraday trades with cautious entry near support and strict stop-loss. Breakout above ₹1,055–1,070 could trigger further upside, but stretched valuations and weak return ratios warrant caution.

Would you like me to extend this into a peer benchmarking overlay comparing Laurus Labs against Divi’s Labs, Aurobindo Pharma, and Dr. Reddy’s for intraday positioning?